The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoter S. Nagi Reddy and persons acting in concert (S. Koni Reddy and S. Manoj Kumar Reddy) of Concord Drugs Limited acquired additional shares through a preferential allotment on 20 November 2025. The promoter group collectively received 5,00,000 voting equity shares and 18,00,000 convertible warrants, totalling 23,00,000 shares (about 17.46% of the pre-allotment capital). Post-acquisition, the promoter group's absolute holding rose from 54,39,204 to 77,39,204 shares, keeping them firmly above the 50% promoter threshold. The company's total equity expanded from 1,00,00,000 to 1,31,75,000 shares because of this preferential issue. The acquisition was done at the allotment stage and not through open-market purchases.
The preferential allotment strengthens the promoter group's already controlling stake, which supports governance continuity but further dilutes non-promoter shareholders' proportional holding. No immediate stock-price catalyst, but the move signals promoter confidence in funding the company's growth.